PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Follow:
183 Articles

New Technologies at Medtech Startups, October 2011

Below is the list of technologies under development by startups identified and…

PatrickDriscoll PatrickDriscoll

Tissue Engineering and Cell Therapy Future Markets

Cell therapy is defined as a process whereby new cells are introduced…

PatrickDriscoll PatrickDriscoll

Minimally Invasive Spine Surgery Patient Registry (SMISS)

The Society for Minimally Invasive Spine Surgery (SMISS) has established a prospective…

PatrickDriscoll PatrickDriscoll

European Obesity Market on Track to Show Drug, Device Gains

The FDA put a slight dent in forecasts for obesity drugs, with…

PatrickDriscoll PatrickDriscoll

VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success

Qnexa, a drug in development by VIVUS, is one of several promising…

PatrickDriscoll PatrickDriscoll

VIVUS, Inc., Presses the Case for Obesity Drug Qnexa, Market Success

Qnexa, a drug in development by VIVUS, is one of several promising…

PatrickDriscoll PatrickDriscoll

Evolution of Spine Surgery Market is Changing the Landscape

The global market for spine surgery devices was estimated to be worth…

PatrickDriscoll PatrickDriscoll

European Diabetes Market

Europe ranks second behind the United States in terms of the largest…

PatrickDriscoll PatrickDriscoll

Changes in the Global Obesity Treatment Market

The obesity treatment market is poised to undergo significant shifts from the…

PatrickDriscoll PatrickDriscoll

Spine Surgery Demand Up as Prices Decline

Demand for solutions to chronic back pain is on the rise.  The…

PatrickDriscoll PatrickDriscoll